Clindamycin/fosmidomycin

Drug Profile

Clindamycin/fosmidomycin

Alternative Names: Fosclin; Fosmidomycin/clindamycin

Latest Information Update: 01 Nov 2014

Price : $50

At a glance

  • Originator Jomaa Pharma
  • Class Antimalarials; Lincosamides; Organophosphorus compounds; Phosphonic acids; Small molecules
  • Mechanism of Action Oxidoreductase inhibitors; Protein 50S ribosomal subunit inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Malaria

Most Recent Events

  • 18 Sep 2014 Discontinued - Phase-II for Malaria in Africa (PO)
  • 18 Sep 2014 Discontinued - Phase-II for Malaria (In children) in Mozambique (PO) (NCT01464138)
  • 18 Sep 2014 Discontinued - Phase-II for Malaria in Asia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top